Gregg Berdy, MD
Ophthalmology · Saint Louis, MONPI 1376541540
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $245,068 of the $360,437 with a category attached, or 68.0%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.8%. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $543.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$71K
- Novartis$47K
- Dompe US, Inc.$40K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$37K
- Sun Pharmaceutical Industries Inc.$32K
- Tarsus Pharmaceuticals, Inc.$30K
- plus $103K from 22 others
Across 93 payments — averaging $4076.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$131K
- Sun Pharmaceutical Industries Inc.$65K
- AbbVie$47K
- Ocular Therapeutix, Inc.$38K
- Kala Pharmaceuticals, Inc.$31K
- Sight Sciences, Inc.$27K
- plus $40K from 9 others
What the payments were for
- Consulting fees$61,87317%
- Speaking & faculty fees$245,06868%
- Travel & lodging$33,6549%
- Food & beverage$19,7975%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 90 | $71,296 |
| Novartis | 107 | $47,320 |
| Dompe US, Inc. | 40 | $40,161 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 38 | $37,489 |
| Sun Pharmaceutical Industries Inc. | 44 | $31,502 |
| Tarsus Pharmaceuticals, Inc. | 34 | $29,579 |
| Aerie Pharmaceuticals, Inc. | 24 | $25,482 |
| Oyster Point Pharma, Inc. | 29 | $22,481 |
| Kala Pharmaceuticals, Inc. | 32 | $19,150 |
| Shire North American Group Inc | 17 | $11,881 |
| AbbVie(2 entities) | 98 | $10,275 |
| Eyevance Pharmaceuticals LLC | 19 | $2,840 |
| Eyepoint US, Inc. | 4 | $2,474 |
| Ocular Therapeutix, Inc. | 10 | $2,283 |
| Glaukos Corporation | 14 | $2,240 |
| Thea Pharma Inc. | 8 | $1,646 |
| Alcon | 31 | $973 |
| Carl Zeiss Meditec USA, Inc. | 1 | $315 |
| Carl Zeiss Meditec, Inc. | 3 | $226 |
| Biotissue Holdings Inc. | 3 | $165 |
| Rxsight Inc | 3 | $156 |
| Harrow Eye, LLC | 3 | $147 |
| Sight Sciences, Inc. | 1 | $90 |
| NEW World Medical,inc. | 3 | $74 |
| Amgen(2 entities) | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 2 | $59 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $54 |
| Tearlab Corp | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$360,437 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $575,219 |
| XiidraLifitegrast | 172 | $186,038 |
| RestasisCyclosporine | 120 | $128,826 |
| VyzultaLatanoprostene Bunod | 194 | $93,586 |
| Lotemax SmLoteprednol Etabonate | 255 | $70,737 |
| LumiganBimatoprost | 111 | $61,645 |
| ProlensaBromfenac Sodium | 137 | $56,700 |
| XdemvyLotilaner | 23 | $44,069 |
| MieboPerfluorohexyloctane/Pf | 41 | $42,477 |
| CequaCyclosporine | 44 | $36,966 |
| RhopressaNetarsudil Mesylate | 57 | $30,917 |
| AzasiteAzithromycin | 47 | $28,908 |
| LotemaxLoteprednol Etabonate | 40 | $18,163 |
| Cyclosporine | 19 | $11,736 |
| VascepaIcosapent Ethyl | 34 | $10,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $40,161 | $575,21912 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo, Zirgan | $71,296 | $329,995424 claims |
| AbbVieRestasis, Lumigan, Combigan | $10,275 | $197,422250 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Lotemax, Besivance, Loteprednol Etabonate | $37,489 | $155,634481 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $29,579 | $44,06923 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $25,482 | $41,33375 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $31,502 | $36,96644 claims |
| AlconSimbrinza | $973 | $10,61727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
- Sean EdelsteinSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.